Process for preparation of dry, expandable, spongy biomaterials for implants

By applying compressive force and drying treatment in high-content water removal liquid, the stability and expansion of the sponge-like material are improved, and the problems of loss of flexibility and long-term use during the drying process are solved, achieving effective in the body Compensate the effect of blood flow and stopping bleeding within a short period of time.

CN119053353APending Publication Date: 2024-11-29BIOTRONIK AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380034335.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-29
Filing Date
2023-04-06
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing sponge-like materials used for medical intervention lose flexibility during drying, difficult to fold and bend, and due to their resorption, they cannot be used in the body for a long time, and cannot effectively solve the problem of long-term application such as perival leakage. Problem, and the drying process leads to irreversible damage to the material, affecting its application effect in the blood.

Method used

By exposing the biomaterial to a high content of water-removing liquid and repeatedly applying compressive forces in multiple compression intervals, combined with the drying process, the stability and expansion of the material are improved so that it can be stored in a dry environment and in contact with Blood expands when used for compact delivery and to compensate for blood flow in the body.

Benefits of technology

The compact storage and delivery of biomaterials is achieved, and it can be used in the body for a long time, reducing perival leakage, improving biocompatibility, reducing the risk of thromboembolic, and stopping undesired bleeding in a short period of time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119053353A_ABST
    Figure CN119053353A_ABST
Patent Text Reader

Abstract

The present invention relates inter alia to a method of preparing a biological material for medical applications comprising exposing the biological material to a first liquid, for example comprising at least 10% of a component other than water, and applying a first compression step to the biological material, wherein the first compression step comprises repeatedly applying a compression force at a plurality of compression intervals. The method further includes drying the biological material.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] Various medical interventions need to stop undesirable bleeding. Such medical interventions include, for example, dental surgery, in which a spongy material may be placed in a bleeding area of ​​the patient's oral cavity (cavitas oris). The spongy material may preferably be adapted to trigger blood coagulation, thereby stopping bleeding.

[0002] A similar need to stop blood flow may occur in transcatheter aortic valve implantation (TAVI), during which a defective aortic valve can be replaced by means of a catheter-based intervention. During TAVI, a new aortic valve can be attached to a (self-expanding) stent and delivered to the patient's heart by inserting a catheter into the patient's femoral artery (arteria femoralis) and then moving the catheter into the patient's heart via the femur. This minimally invasive surgery can significantly reduce the patient's risk because it may be caused by conventional replacement of the aortic valve that may require opening the patient's chest. However, an undesirable side effect of TAVIs may be the formation of paravalvular leaks. This paravalvular leak can be understood as a gap between the implanted aortic valve and the inner wall of the patient's peripheral blood vessels (i.e., the aorta), where the paravalvular leak can allow blood to flow back from the aorta into the ventricle. This may lead to a loss of physiological performance and / or dyspnea in the patient. Paravalvular leaks can be compensated at least in part by wrapping a spongy and / or expandable material (e.g., as a sealing element similar to an O-ring) around the stent and the new aortic valve so that the expandable material can at least partially close the paravalvular leak.

[0003] These known materials are generally based on bacterial nanocellulose, decellularized tissue matrix (e.g., pericardium, colon or rumen) and collagen-based sponges. However, these materials exhibit various disadvantages. It is noteworthy that bacterial cellulose is a fairly new material, and in view of the tolerance and durability in medical applications, it only has limited clinical long-term data. Collagen-based sponges are preferably used for applications in dentistry. However, since they are generally used as natural materials (and, for example, are resorbable), their potential range of applications is very limited. In particular, due to their resorbable properties, they are inherently unsuitable for applications in which collagen-based sponges need to be used for a long time. This essentially excludes collagen-based sponges for treating, for example, paravalvular leaks, in which collagen-based sponges may need to be retained in the patient's heart for, for example, several years. A sponge is a porous material with holes.

[0004] The preparation of the materials generally involves a drying step (e.g., reducing the water content in the biomaterial to less than 10 wt.%), such as by freeze drying. However, as a result of the drying process, these materials generally exhibit limited flexibility or even lose their flexibility, which makes their handling uncomfortable or even impossible for some applications. For example, conventionally dried materials may not be foldable or bendable to the extent that some medical applications (e.g., in combination with stents) may require.

[0005] Furthermore, conventional drying procedures in air often lead to irreversible damage of the material and / or may result in a certain undesirable brittleness of the material. These disadvantages may additionally be accompanied by undesirable changes in the shape of the material upon drying. These adverse effects may also persist even after the material has been exposed to blood, for example in medical applications, so that they may no longer be able to perform the tasks for which they were originally designed.

[0006] In other manufacturing methods of biomaterials, a more advanced "stabilization drying" process may be undergone, in which one or more chemical stabilizers may be integrated in a sequential rinsing process. However, due to the typical spongy texture of the material, this only rinsing process usually provides only limited stabilization of the material, because the stabilizer (e.g., stabilization fluid) may only enter the spongy material in a limited way due to the typical porous structure of the material. In other words, the stabilization fluid may only enter the areas of the material located outside the material, while the stabilization fluid may not penetrate into the central part of the material. Therefore, sufficient stabilization of the material may not be ensured, and the desired properties of the material, in particular with regard to flexibility without causing irreversible structural damage, may not be fully achieved.

[0007] Therefore, biomaterials for medical applications known in the art as well as the related methods of manufacturing and preparing them for medical applications do not always fulfill the desired requirements of medical applications in a satisfactory manner.

[0008] Therefore, there is a need to improve methods of making biomaterials for medical applications and to provide biomaterials for use in prior art medical applications with improved properties. Summary of the invention

[0009] Aspects of the present invention at least partially satisfy this need.

[0010] A first aspect relates to a method of preparing a biomaterial for medical applications. The method may include exposing the biomaterial to a first liquid, wherein the first liquid may, for example, contain at least 10% of a component other than water. Furthermore, the method may include applying a first compression step to the biomaterial, wherein the first compression step may include repeatedly applying a compressive force in a plurality of compression intervals. The method may also include drying the biomaterial, for example at least partially drying the biomaterial after the first compression step.

[0011] The first liquid may contain, for example, at least 10% by weight of components other than water. Alternatively, the first liquid may include, for example, at least 10% by volume of components other than water. In some embodiments, the first liquid may include, for example, at least 20%, 30%, 40%, 50%, 60% or 70% of components other than water (by weight or volume).

[0012] In a preferred embodiment, the first liquid may comprise a stabilizing solution and / or a flushing fluid.For example, the first liquid may contain at least 10% of a stabilizing agent, such as polyethylene glycol (PEG), such as PEG-200 or PEG-400, and / or glycerol.

[0013] The compressive force may be applied to the biomaterial in at least two compression intervals, preferably at least three, four or five compression intervals.The compressive force may be applied to the biomaterial such that it at least temporarily reduces the thickness of the biomaterial.

[0014] The above method can provide the following advantages: providing a dry biomaterial for medical applications, which has a reduced size and can be stored in a dry environment (e.g., in the absence of a preservation liquid). In addition, the biomaterial can have swelling properties when exposed to a liquid (e.g., blood). These swelling properties can allow the biomaterial with a reduced volume to be delivered to a specific location in the patient's body, for example, through catheter-based delivery, at which location the biomaterial can increase its volume due to contact with blood. This can allow for space-saving delivery of the biomaterial. In addition, due to the expansion of the biomaterial when in contact with, for example, blood, the biomaterial can expand into a small cavity in the patient's body (e.g., in a wound / lesion), where the biomaterial can assist in blood clotting, so that undesirable bleeding and / or blood flow can be stopped.

[0015] Furthermore, in addition to the above advantages, the method may allow providing a biomaterial with improved long-term durability, such that the biomaterial may be particularly suitable for reducing undesirable side effects in TAVI, for example, for at least partially compensating for paravalvular leaks where the biomaterial may remain in the patient (e.g., for several years). The biomaterial may generally be applied in any kind of surgery, for example, where it is preferably necessary to reduce and / or stop the flow of blood or any other body fluid.

[0016] Another advantage of biomaterials can essentially be seen in increased biocompatibility, as synthetic materials may not be used, which may help reduce the risk of thromboembolic complications.

[0017] Repeated application of a compressive force after or while the biomaterial is exposed to the first liquid can increase penetration of the biomaterial by the first liquid. For example, if the first liquid includes a flushing fluid, this can result in improved displacement of, for example, a previously applied crosslinking agent (e.g., glutaraldehyde). In addition, if the first liquid includes a stabilizer, penetration of the stabilizer into the biomaterial can be improved, and more water can be displaced from the material, resulting in improved drying. In some examples, the formation of hydrogen bridges that may lead to irreversible bonding (even upon rehydration) during drying can therefore be reduced.

[0018] Repeated application of the compressive force may include alternating compression intervals and at least one relaxation interval of the biomaterial.

[0019] In some preferred embodiments, the compression interval may be followed by at least one relaxation interval, wherein, during the at least one relaxation interval, the compressed biomaterial is allowed to return to its state before the application of the compressive force, so that, for example, a reduction in the thickness of the biomaterial (e.g., due to the application of the compressive force) can be at least partially reversed.

[0020] The compression force may be configured to be equal in magnitude during each of the alternating compression intervals. Alternatively, the compression force may be reduced with each subsequent compression interval. Alternatively, the compression force may be increased between each subsequent compression interval.

[0021] By applying a compressive force with alternating compression intervals and at least one relaxation interval, it is possible to ensure that the saturation / impregnation of the biomaterial with (at least) the first liquid is improved. More specifically, during each compression interval, the first liquid (and / or other liquids) residing in the biomaterial can be displaced from the biomaterial, and in the relaxation interval, the first liquid can be (again) soaked into the biomaterial. Repeating the process can result in an increase in the amount of the first liquid in the biomaterial, and the penetration depth of the first liquid into the biomaterial can be increased. This can help the biomaterial to be saturated with the first liquid. If the first liquid is a stabilizing liquid, an improved stabilization process can therefore be supported.

[0022] At least one relaxation interval may comprise 0.2s to 30s, preferably 0.5s to 15s. In a preferred embodiment, at least one relaxation interval may be provided with a duration of about 3s to 7s, for example about 5s.

[0023] If the biological material is exposed to at least two relaxation intervals, the at least two relaxation intervals may be of equal duration. Alternatively, the duration of the relaxation interval may increase or decrease with each subsequent relaxation interval.

[0024] By adjusting at least one relaxation interval so that it comprises 0.2 s to 30 s, an optimized impregnation of the biomaterial with the first liquid can be ensured, since a shorter relaxation interval may not ensure that the biomaterial has a sufficient amount of time to soak with a sufficient amount of the first liquid, which sufficient amount of the first liquid can then allow the desired degree of stabilization of the biomaterial, for example (if the first liquid is a stable solution). On the other hand, if a relaxation interval longer than the above interval is selected, the production of the biomaterial for medical applications may take an excessively long time.

[0025] The compression interval may comprise 0.1 s to 10 s, preferably 0.2 to 5 s. In a preferred embodiment, at least one compression interval may be provided with a duration of about 1 s to 3 s, for example about 2 s.

[0026] If the biological material is exposed to at least two compression intervals, the at least two compression intervals may be of equal duration. Alternatively, the duration of the compression interval may be increased or decreased between each subsequent compression interval.

[0027] By adjusting the compression interval so that it comprises 0.1 s to 30 s, an optimal distribution of the first liquid within the biomaterial can be ensured and unwanted spraying of liquid within the biomaterial can be eliminated. However, if the duration of the compression interval is selected to be longer than the above interval, the production of the biomaterial may take excessively long time.

[0028] The first compression step may include applying a compressive force in the range of 25 kPa to 500 kPa, preferably 50 kPa to 450 kPa. In a preferred embodiment, the compressive force may be 70 kPa to 80 kPa, such as about 74 kPa, or 350 kPa to 400 kPa, such as about 370 kPa. For example, these values ​​have proven to be very suitable for biomaterials including pericardium.

[0029] The compressive force may be applied to the biomaterial across its entire major surface. For example, if the biomaterial is provided as a sheet material, the compressive force may be applied perpendicularly to the front and back sides of the sheet.

[0030] Configuring the first compression step such that the compression force is within the above range can ensure that the biomaterial can be reproducibly compressed to a certain desired thickness. As the applicant has discovered, higher compression forces may result in a dispersion of the thickness values ​​of the biomaterial obtained (after completion of the method), and therefore may not result in the properties of the biomaterial in a reproducible manner (e.g., relative to the thickness of the biomaterial and / or its volume). In addition, higher compression forces may also damage the biomaterial, while compression forces that are too weak to compress the biomaterial may not result in the above exchange of the first liquid in the biomaterial, and therefore may not result in the desired degree of crosslinking or stabilization in the biomaterial.

[0031] The method may further comprise exposing the biological material to a second liquid comprising, for example, at least 10% of a component other than water. The exposure to the second liquid may be performed after the exposure to the first liquid.

[0032] The method may further comprise applying a second compression step to the biomaterial. The second compression step may be performed, for example, during exposure of the biomaterial to the second liquid. The second compression step may be similar to the first compression step and include, for example, the features described herein with reference to the first compression step.

[0033] The second liquid may include a different composition than the first liquid. The second liquid may include, for example, at least 10% by weight of components other than water. Alternatively, the second liquid may include, for example, at least 10% by volume of components other than water. In some embodiments, the second liquid may include, for example, at least 20%, 30%, 40%, 50%, 60% or at least 70% of components other than water (by weight or volume).

[0034] For example, the second liquid may include a flushing solution and / or a stabilizer. If the second liquid comprises a stabilizer, it may preferably comprise polyethylene glycol (PEG), such as PEG-200 or PEG-400, and / or glycerol.

[0035] Applying at least two stabilizer solutions (e.g., if the first liquid is a first stabilizer solution and if the second liquid is a second stabilizer solution) can enhance stabilization of the biomaterial. In this embodiment, the first and second pressing steps can be performed during exposure of the biomaterial to the first and second stabilizers, respectively. In other examples, the first liquid can include or be a flushing solution, and the second liquid can include or be a stabilizer.

[0036] The method may further include: after the second compression step, exposing the biomaterial to a third liquid, the third liquid comprising at least 10% of a component other than water. The method may further include: applying a third compression step to the biomaterial. The third compression step may be similar to the first compression step and include, for example, those features described herein with reference to the first compression step.

[0037] The third liquid may include a different composition than the first liquid. The third liquid may include a different composition than the second liquid. The third liquid may include, for example, at least 10% by weight of components other than water. Alternatively, the third liquid may include, for example, at least 10% by volume of components other than water. In some embodiments, the third liquid may include, for example, at least 20%, 30%, 40%, 50% or at least 60% of components other than water (by weight or volume).

[0038] The third liquid may be an aa stabilizer. The third liquid may preferably comprise polyethylene glycol (PEG), more preferably PEG-400 and / or PEG-200 and / or glycerol.

[0039] In some embodiments, the method may further include exposing the biomaterial to a fourth liquid, a fifth liquid, a sixth liquid, a seventh liquid, etc. Exposing the biomaterial to the fourth liquid, the fifth liquid, the sixth liquid, the seventh liquid, etc. may be accompanied by applying a corresponding fourth compression step, a fifth compression step, a sixth compression step, a seventh compression step, etc. to the biomaterial. The corresponding exposure times may be similar to or equal to the exposure times described herein with reference to the first liquid, the second liquid, and the third liquid described above.

[0040] Drying may include drying the biological material on a material comprising the first, second and / or third liquid. Drying may be performed in a climate cabinet and / or a desiccator.

[0041] Drying may be adjusted such that it may primarily reduce the amount of water (eg of the first liquid, the second liquid, the third liquid, etc.) and / or (excess residual) stabilizer in the biological material.

[0042] The drying process may further comprise applying a compressive force to the biomaterial.The compressive force may be applied to the biomaterial during the entire drying process or only during at least a portion of the drying process or after the drying process.

[0043] The drying process can be carried out at room temperature (e.g., at about 20°C). Alternatively, the drying process can also be carried out above room temperature (e.g., at 30°C, 40°C, 50°C, 60°C, 80°C, etc.). Alternatively, the drying process can also be carried out below room temperature (e.g., at 18°C). The drying process can preferably be carried out at a constant temperature. However, in some embodiments, a change in temperature may be advantageous.

[0044] The material impregnated with liquid can be used as a reservoir, which is suitable for providing liquid to the biological material during the drying process. The material impregnated with liquid can be a sheet-like element or a towel-like element. Alternatively, the material impregnated with liquid can be a grid-like structure, which has been covered with liquid before the biological material is placed on it.

[0045] In some embodiments, the material may also be impregnated with a fourth liquid or the like.

[0046] By performing the drying process in a material impregnated with the first, second or third liquid, it is possible to avoid that the drying process extracts an excessive amount of the corresponding liquid (e.g., stabilizer) from the biological material. The stabilizer extracted from the biological material (due to the drying process) can be replaced by the stabilizer from the impregnated material, so that a certain amount of stabilizer can be maintained in the biological material. Therefore, undesirable degradation of the biological material during the drying process can be avoided.

[0047] The method may reduce the thickness of the biomaterial by 40-80% or 50-70% compared to the initial thickness of the biomaterial. The reduction in thickness may preferably be about 60%.

[0048] After compressing the biomaterial, for example in a climate cabinet, the method can reduce the thickness of the biomaterial by 50-70%, wherein the reduced thickness is maintained in this range for at least 1-7 days (for example, after 1 day, 2 days, 3 days, 4 days, 5 days, 6 days or 7 days).

[0049] Additionally or alternatively, the method may also reduce the surface area of ​​the biomaterial by 10-30%, preferably by about 15%. The surface area may be associated with the metric dimensions (e.g., width and length) of the region subjected to the compressive force as described above, e.g., where the biomaterial is provided in sheet form.

[0050] By reducing the thickness (and surface area) of the biomaterial, a compact biomaterial for medical applications may be provided. This may in particular allow the biomaterial to be delivered and / or inserted into narrow blood vessels and / or lesions in a patient.

[0051] The first, second and / or third liquid may comprise at least 10% of a stabilizing agent, such as glycerol and / or polyethylene glycol PEG. The first liquid may alternatively comprise a flushing solution.

[0052] In exemplary embodiments where the first, second and / or third liquids include glycerol, the glycerol may be provided at a concentration of 10-50%, preferably 20-30%.

[0053] In exemplary embodiments where the first, second and / or third liquid comprises polyethylene glycol, PEG may be provided at a concentration of 10-50%, preferably 20-40%.

[0054] By providing the first liquid such that it comprises glycerol and / or PEG, preferably in the above mentioned concentrations, an optimized stabilization of the biological material may be obtained.

[0055] In some embodiments, wherein the first liquid or the second liquid comprises a rinse solution, a saline solution may also be used, which may contain less than 10% of components other than water (e.g., NaCl may be provided as a 0.9% solution). In addition, ultrapure water may be used, for example. Thus, it is also a separate aspect to apply one or more (pulse) compression steps as described herein to the biomaterial prior to drying the biomaterial, e.g., during exposure to the liquid.

[0056] The biomaterial may include pericardial tissue. The pericardial tissue may preferably be porcine pericardium. Alternatively or additionally, the biomaterial may additionally or alternatively include other biomaterials, which may preferably include collagen fibers. By providing the biomaterial as pericardial tissue, the biocompatibility of the biomaterial in the patient's body may be increased. In addition, by using porcine pericardial tissue, the acquisition cost of the biomaterial may be reduced and a cost-effective biomaterial for medical applications may be provided. In other embodiments, the biomaterial may include, for example, colon or rumen tissue.

[0057] In a preferred embodiment, the biomaterial may (initially) comprise native (ie natural) biomaterial. Additionally, the biomaterial may comprise decellularized biological tissue.

[0058] Another aspect relates to a biomaterial that can be prepared according to one of the above method steps.By providing a material manufactured according to one of the above method steps, a highly swellable storable (in a dry environment), sponge-like and expandable / swellable material for medical applications can be provided.

[0059] The biomaterial can swell to at least 70%, preferably at least 80%, such as 80-90%, of its initial thickness upon rehydration, such as upon contact with an aqueous liquid. Additionally or alternatively, the biomaterial can swell to at least 70%, preferably at least 80%, of its initial surface area upon rehydration, such as upon contact with an aqueous liquid.

[0060] In a preferred embodiment, the biomaterial prepared according to one of the above method steps may be provided in a reduced size compared to the initial size of the biomaterial.

[0061] The biomaterial may be expandable / swellable due to rehydration of the biomaterial.Rehydration may be induced upon exposure of the biomaterial to a liquid, preferably blood.

[0062] The biomaterial may be adapted such that swelling occurs within a time interval of less than 30 s, preferably less than 20 s, more preferably less than 10 s.

[0063] By providing the biomaterial such that its thickness and / or its area size is expandable, expansion of the biomaterial into a small cavity can be supported so that undesired bleeding can be stopped within a short period of time.

[0064] Another aspect relates to an implant. The implant may comprise a biomaterial prepared according to one of the above method steps.

[0065] The implant may be a stent, preferably a self-expanding stent. The stent may comprise an aortic valve.

[0066] The implant can be provided with the biomaterial such that the biomaterial surrounds the implant in a circumferential direction and such that when the biomaterial expands (eg, in a radial direction) (eg, in response to rehydration), blood flow between the biomaterial and the inner wall of a patient's blood vessel can be prevented.

[0067] A further aspect relates to the use of a material which can be produced according to one of the above-described method steps for a sealing element of an implant.

[0068] By providing an implant with a biomaterial prepared according to one of the above method steps, the risk of undesirable side effects (e.g. paravalvular leak) that may occur during implantation of, for example, an aortic valve can be suppressed, since a possible paravalvular leak can be immediately treated by the expanded biomaterial. The latter step can help to at least help reduce the paravalvular leak.

[0069] With respect to the foregoing disclosure, the present invention also includes the following embodiments:

[0070] 1. A method for preparing a porous tissue sponge, wherein the method comprises the following steps:

[0071] - providing one or more natural biological tissues or one or more decellularized biological tissues containing collagen fibers, preferably pericardial tissue or decellularized pericardial tissue,

[0072] - (dry) mechanical lysis of one or more native biological tissues or one or more decellularized biological tissues, preferably by grinding, to obtain lysed tissues,

[0073] - homogenizing the dissolved tissue to obtain a homogenized tissue,

[0074] - pouring the homogenized tissue into a frozen aldehyde mold, preferably a frozen glutaraldehyde mold, and freezing the homogenized mixture to obtain a frozen tissue,

[0075] - thawing the frozen tissue and the frozen aldehyde mold, preferably glutaraldehyde mold, thereby pre-crosslinking the collagen fibers of the tissue to obtain a porous tissue sponge,

[0076] - Optionally, the porous tissue sponge is further cross-linked by adding an aldehyde, preferably glutaraldehyde, at elevated temperature, such as 60 degrees.

[0077] 2. A method (600) for preparing a biomaterial for medical applications, comprising:

[0078] - providing a porous tissue sponge preferably obtained by the method of embodiment 1,

[0079] - exposing the porous tissue sponge to a glycerol solution;

[0080] - applying a first compression step to the biomaterial, wherein the first compression step comprises repeatedly applying a compressive force at a plurality of compression intervals; and

[0081] - exposing the porous tissue sponge to an aqueous polyethylene glycol solution comprising polyethylene glycol having an average molecular weight of 150 g / mol to 300 g / mol;

[0082] - applying a second compression step to the biomaterial, wherein the second compression step comprises repeatedly applying the compressive force at a plurality of compression intervals; and

[0083] - exposing the porous tissue sponge to an aqueous polyethylene glycol solution comprising polyethylene glycol having an average molecular weight of 300 g / mol to 1000 g / mol;

[0084] - applying a third compression step to the biomaterial, wherein the third compression step comprises repeatedly applying the compression force in a plurality of compression intervals to obtain a stable tissue sponge; and

[0085] - drying the stable porous sponge tissue to obtain a dry sponge; and

[0086] -Optionally compress the dried sponge.

[0087] 3. The method of embodiment 2, wherein the repeated application of the compressive force comprises alternating compression intervals and at least one relaxation interval of the biomaterial.

[0088] 4. The method according to embodiment 3, wherein the at least one relaxation interval comprises 0.2s to 30s, preferably 0.5s to 15s.

[0089] 5. The method according to any one of embodiments 2 to 4, wherein the compression interval comprises 0.1s to 10s, preferably 0.2s to 5s.

[0090] 6. The method according to any one of embodiments 2 to 5, wherein the first compression step comprises applying a compressive force in the range of 25 kPa to 500 kPa, preferably 50 kPa to 450 kPa.

[0091] 7. The method according to any one of claims 2 to 6, wherein the drying is performed by reducing the relative humidity to 10% or less at 30°C to 40°C, preferably 37°C.

[0092] 8. The method according to any one of claims 1 to 8, wherein the method reduces the thickness of the biomaterial by 40-80%, preferably 50-70%, compared to the initial thickness of the biomaterial.

[0093] 9. The method according to any one of claims 2 to 9, wherein the porous tissue sponge is based on pericardial tissue.

[0094] 10. A method according to any one of claims 2 to 9, wherein the dry sponge is compressed by applying a compressive force of 50 kPa to 300 kPa.

[0095] 11. A method according to any one of claims 2 to 9, wherein the dry sponge is compressed by applying a compressive force of 70 kPa to 80 kPa.

[0096] 12. Biomaterial prepared by the method according to any one of claims 1 to 11.

[0097] 13. The biomaterial of claim 12, wherein the biomaterial is swellable upon rehydration to at least 70%, preferably at least 80%, of its initial thickness; and / or the biomaterial is swellable upon rehydration to at least 70%, preferably at least 80% of its initial surface area.

[0098] 14. Implant comprising the biomaterial according to claim 12 or 13.

[0099] 15. Use of a biomaterial prepared according to the method of any one of claims 1 to 11 for a sealing element of an implant. BRIEF DESCRIPTION OF THE DRAWINGS

[0100] The following drawings are provided to support the understanding of the present invention:

[0101] Figure 1A-1B : Illustration of an exemplary air-dried piece of pericardial material before and after rehydration;

[0102] Figure 2A-2C : Illustration of an exemplary mold of dissolved biomaterial for ice molding;

[0103] Figure 3A-3B : Example box plots showing the reduction in thickness and surface area of ​​biomaterials after different processing steps;

[0104] Figure 4A-4D : Example images of biological material taken with a scanning electron microscope;

[0105] Figure 5 : An exemplary comparison of different samples of biological material exposed to different combinations of stabilizing solutions;

[0106] Figure 6 : Illustration of an exemplary process for manufacturing biomaterials for medical applications. DETAILED DESCRIPTION

[0107] Figure 1A and Figure 1B The sponge-like piece processed from porcine pericardial tissue that is conventionally dried in air is shown as an example. More specifically, Figure 1A Air-dried pericardial tissue is shown in a dry state. The pericardial tissue piece is initially provided as a sheet of material having a rectangular surface. Figure 1A As depicted in , the pericardial tissue acquires a curved and uneven shape and loses its rectangular shaped surface due to the air drying process and due to the associated water loss. In particular, the extraction of water from the pericardial tissue causes the pericardial tissue to become brittle and inflexible (i.e., non-deformable), which is associated with irreversible damage to the internal structure of the pericardial tissue.

[0108] Figure 1B The pericardial tissue is shown in a state where it has been rehydrated (eg, exposed to a fluid, such as water). Figure 1A Pericardial tissue. Figure 1B As described in Figure 1A Compared to the pericardial tissue shown in , the pericardial tissue acquires an even more degraded and deteriorated external shape after rehydration.

[0109] from Figure 1A and Figure 1B The results depicted in , lead to the conclusion that exposing a piece of pericardial tissue to conventional drying procedures irreversibly damages the pericardial tissue and does not result in desirable properties of the pericardial tissue required for medical applications (such as, for example, flexibility, etc.).

[0110] Figure 2A-2C Different tools are shown, which can be used to transform a starting biomaterial (preferably pericardial tissue) into a (sponge-like) material of a desired shape.

[0111] It is worth noting that Figure 2A Three different molds made of different materials are shown that can be used to form a mold, such as glutaraldehyde, for shaping dissolved biomaterial.

[0112] refer to Figure 2A , the mold 100 is made of polylactic acid (PLA), the mold 200 is made by selective laser sintering (SLA), and the mold 300 is made of polyoxymethylene (POM). Figure 2A As shown, each exemplary mold 100, 200, 300 is provided with an inner volume in the shape of a rectangular parallelepiped.

[0113] Figure 2B Shown is suitable for closing Figure 2A An exemplary cover of a mould 100, 200, 300 is shown. The exemplary cover may preferably be made of silicone and may be provided with a protruding element 1 having a rectangular cross section.

[0114] According to one aspect of the present invention, Figure 2A One of the exemplary molds shown may be filled with a glutaraldehyde solution (preferably at a concentration of about 0.1 to 5%, such as about 0.5%) and formed by Figure 2B The exemplary cover shown covers. Figure 2B The lid of can cover the mold so that the protruding element 1 enters the glutaraldehyde solution. The mold filled with the glutaraldehyde solution can then be frozen.

[0115] Figure 2C The glutaraldehyde solution is shown in FIG. Figure 2A After the freezing process, the lid can be removed from the corresponding mold and rectangular recesses 2 are formed in the frozen glutaraldehyde block at the locations where the protruding elements 1 came into contact with the glutaraldehyde during the freezing process. Figure 2C The block can be used as a mold (also referred to as a template in this article).

[0116] In a subsequent step, the initial biomaterial (preferably porcine pericardium) can be dissolved (as will be further described below). The dissolved biomaterial can then be filled into the rectangular recess 2 of the template (e.g., by syringe, while avoiding the formation of bubbles in the dissolved biomaterial) and can be frozen at a temperature of up to -20°C. During the freezing process, ice crystals can usually form in the dissolved biomaterial, which can lead to the formation of a sponge-like / porous structure in the biomaterial (e.g., so that the material can be compressible at room temperature, liquid can enter the pores after thawing, etc.).

[0117] After the initially dissolved biomaterial is completely frozen, it can be thawed (slowly) at room temperature. During the thawing process, the biomaterial can be cross-linked and at least partially stabilized by the melted glutaraldehyde. As described in further detail below, during the subsequent stabilization step, the stabilizing effect can be additionally enhanced.

[0118] It should be noted that the shape of the initial mold (such as Figure 2A ) and the shape of the cover (as shown in the example Figure 2B The glutaraldehyde template thus obtained can be provided in any possible shape. Therefore, such an ice molding procedure can facilitate that the biomaterial can be provided in a variety of different shapes, so that the biomaterial can be suitable for a wide range of different applications. This process is also called ice molding.

[0119] Figure 3A and 3B An exemplary box plot is shown indicating the thickness at different stages of the biomaterial manufacturing process measured in the test series ( Figure 3A ) and surface area ( Figure 3B) decrease.

[0120] Figure 3A It is shown that after applying stabilization-related steps to the biomaterial (eg, after exposing the biomaterial to the first, second, and third liquids and the related compression steps as described herein), the biomaterial obtains a reduced thickness.

[0121] Figure 3A It is further shown that as a result of stabilization, the thickness of the biomaterial can be reduced from 100% to about 60-90% or 65-80% of the initial thickness of the biomaterial. Additional compression (pressing) of the biomaterial, preferably at 74 kPa at room temperature, e.g., after drying as described herein (see, e.g., as described below in reference Figure 6 The exemplary processing step 615) described above can result in a further reduction in the thickness of the biomaterial to approximately 30-55% or 35-50% of the initial thickness of the biomaterial.

[0122] Subsequent storage of the biomaterial in a desiccator for several days (data for 1, 2, 3, 4, 7 days are shown) did not result in a significant change in the thickness of the biomaterial compared to its initial thickness. Thus, the material can be prepared in a stable state.

[0123] Figure 3A It is further depicted that rehydration of the pressed biomaterial can result in thickness recovery to 100% of the original thickness of the biomaterial.

[0124] Figure 3B shows that depending on the reference Figure 3A Reduction of the surface area of ​​the biomaterial processing steps described. It should be noted that, in addition to reducing the thickness of the biomaterial, a reduction in surface area is generally considered to be advantageous because it results in a reduction in the volume of the biomaterial. This may particularly allow the application of the biomaterial in minimally invasive applications, for which only small pieces of biomaterial may be used.

[0125] Similar to the reduction in thickness, the stabilization treatment also results in a reduction in surface area in the range of 85-99% of the original surface area of ​​the biomaterial, for example about 90-95%. Additional compression (pressing) of the biomaterial, preferably at room temperature at 74 kPa, and preferably after drying, for example as described herein, can result in a further reduction in the surface area of ​​the biomaterial to about 75-85% of the initial surface area of ​​the biomaterial. This result can be based on the following aspects: the biomaterial can preferably be placed on a special filter paper, during the compression of the biomaterial, the special filter paper can absorb (excess) stabilizer solution leaking from the biomaterial due to the applied compression force. As a result, the biomaterial may also shrink relative to the surface area of ​​the biomaterial.

[0126] Subsequent storage of the biomaterial in a desiccator showed a slight further decrease in surface area to about 65-80%. Further storage in a desiccator for several days (data for 2, 3, 4, 7 days are shown) did not result in significant further changes in the surface area of ​​the biomaterial compared to its initial surface area. Thus, the material can be prepared in a stable state.

[0127] Figure 3B It is further depicted that rehydration of the compressed biomaterial can result in restoration of the surface area to 100% of the original surface area of ​​the biomaterial.

[0128] Figures 4A-4D Shown are images of a biomaterial (porcine pericardium) taken with a scanning electron microscope after exposing the biomaterial to different processing steps as outlined herein. It is emphasized that Figures 4A-4D They were shot at the same scale.

[0129] Figure 4A Shown after crosslinking and washing but before application of stabilizer (e.g., in reference Figure 6 A cross-sectional view of the biological material in a state (as may be obtained after step 609) is outlined. In particular, Figure 4A The internal fiber structure of the biomaterial is shown.The thickness of the sheet-like biomaterial may comprise about 0.2 to 5 mm, such as about 0.5 to 2 mm, or about 1 to 1.5 mm.

[0130] Figure 4B Shown after applying stabilization, drying and final compression steps to the biomaterial (e.g., in reference Figure 6 A cross-sectional view of the biological material after step 615 is shown in FIG. Figure 4B As shown, the initial thickness of the biomaterial ( Figure 4A ) compared to the biomaterial.

[0131] This can also be Figure 4C Seen in Figure 4C Shows Figure 4B Magnified view of the sample shown in . Figure 4C It is shown that as a result of the application of the stabilization step the fibers of the biomaterial have additionally been covered with a protective layer of the stabilization solution. Reference numeral 3 exemplarily highlights an exemplary region showing the protective layer as a slightly blurred fiber structure.

[0132] Figure 4D It shows that Figure 4B and 4C A cross-sectional view of the biomaterial after rehydration of the (compressed) biomaterial shown. Figure 4D As shown, the biomaterial almost recovered to its initial thickness after rehydration. Figure 4B and4C compared to, Figure 4D It is also shown that as originally Figure 4A The fiber structure depicted in the figure re-expands due to rehydration. Figure 4D It was also shown that no irreversible damage occurred in the internal fiber structure of the biomaterial due to the processing steps and rehydration.

[0133] all in all, Figures 4A-4D The internal structure of the biomaterial after applying several processing steps as outlined herein is shown. In particular, Figure 4A and 4D The comparison shows that even after the application of the processing steps, the initial properties of the biomaterial ( Figure 4A ) can also be performed after rehydration of the biomaterial ( Figure 4D ) to regain.

[0134] Figure 5 A comparison of the effects of applying different combinations of stabilizing solutions and their concentrations to a dried sample of a biomaterial, hereafter referred to as a reengineered pericardial sponge (RPS), is shown. Figure 5 For comparison, different samples of biomaterials with initially identical dimensions have been prepared. Each initially prepared sample was then exposed to a different combination of stabilizing solutions. Each biomaterial sample was exposed to each stabilizing solution for 15 minutes. The resulting biomaterials Figure 5 Samples a)-e) were directly compared with each other.

[0135] Sample a) shows the biomaterial after being exposed to glycerol at a concentration of 20% (first liquid), 30% (second liquid) and 40% (third liquid) three times. During each exposure time, pulse compression is applied as outlined herein (same for all exposure times and samples). Sample a) depicts that the combination of the stabilizing solutions used leads to excellent results, i.e., the biomaterial exhibits flexibility and does not become brittle. In addition, sample a) also maintains its external shape and size. In some examples, glycerol at a concentration of 15-25%, glycerol at a concentration of 25-35%, and glycerol at a concentration of 35-45% can be used.

[0136] Sample b) shows another sample of the biomaterial after exposure to glycerol (at a concentration of 30%), PEG-200 (at a concentration of 40%), and PEG-400 (at a concentration of 40%). Sample b) also exhibited no loss of flexibility, and sample b) did not become brittle. It has been determined that the combination of stabilizing solutions applied to sample b) is a preferred combination of stabilizing solutions. In some instances, concentrations of 25-35% glycerol, 35-45% PEG-200, and 35-45% PEG-400 may be used.

[0137] Sample c) shows the biomaterial after exposure to glycerol (at a concentration of 30%) and PEG-200 (at a concentration of 40%). Sample c) lacks a third stabilization step (compared to samples a) and b). After rehydrating sample c), sample c) no longer fully forms an acceptable thickness (e.g., greater than 90% of the initial thickness of the biomaterial) after rehydration, which may be due to the lack of a third stabilization step. The combination of stabilizing solutions applied to the biomaterial relative to sample c) may be good for some applications, but it may be improved by the third stabilization step applied to samples a) and b).

[0138] Sample d) shows the biomaterial after exposure to glycerol (5% concentration), PEG-200 (10% concentration) and PEG-400 (10% concentration). Figure 5 As can be seen in the graphs, sample d) shows deformation, loss of flexibility and sample d) becomes brittle after the stabilization step is applied. It can therefore be concluded that the combination of stabilization solutions applied to sample d) leads to unsatisfactory properties of the biomaterial. This may be caused by the reduced concentration of the stabilization solution used to treat sample d) (compared to sample b)).

[0139] Sample e) shows the biomaterial after exposure to glycerol (10% concentration), PEG-200 (10% concentration) and PEG-400 (20% concentration). Figure 5 As can be seen in the graphs, sample e) shows deformation, loss of flexibility and sample e) becomes brittle after the stabilization step. It can therefore be concluded that the combination of stabilization solutions applied to sample e) leads to unsatisfactory properties of the biomaterial. This can be explained by the reduced concentration of the stabilization solution used to treat sample e) (compared to sample b)).

[0140] It can be concluded that the choice of the selected stabilizing solution and the selected stabilizing solution concentration has a serious impact on the properties of the biomaterial, for example in terms of flexibility, rehydration properties and brittleness.

[0141] The following table further shows an overview of the surface areas obtained after stabilizing the biomaterial in different sequences of stabilizer solutions after the compression step, after 1 day of storage of the biomaterial and after 2 days of storage of the biomaterial. The table refers to the surface areas obtained (in percentage) relative to the initial surface area of ​​the biomaterial.

[0142]

[0143] Table 1: Comparison of surface area reduction of biomaterials according to the applied stabilization solution and the applied treatment steps.

[0144] As shown in the table above, exposing the biomaterial to glycerol three times resulted in the most significant reduction in the biomaterial surface area.

[0145] Figure 6 An exemplary process diagram of a manufacturing process 600 of an initial biomaterial piece and its preparation for medical applications is shown.

[0146] The manufacturing process may start at step 601, where biological material (e.g., pericardial material) may be obtained from a slaughterhouse. The pericardial material may preferably be stored in a saline solution (e.g., a NaCl solution having a concentration of 0.5-1.5%, preferably 0.9%) at a temperature of 1-5°C, preferably 4°C, for 2 hours.

[0147] In step 602, pericardial material may be dissected in a wet NaCl environment (having a concentration of 0.5-1.5%, preferably 0.9%). Dissection may include removing fat and / or fascia from the pericardium. Step 602 may further include (roughly) cutting the pericardial material into a desired geometry.

[0148] In step 603, the pericardial material may be flushed in 100 ml of NaCl (having a concentration of 0.5-1.5%, preferably 0.9%) while gently moving the pericardial material.

[0149] In step 604, the pericardial material can be dissolved, including a homogenization step, which can be based at least in part on the mechanical interaction of the pericardial material with a plurality of ceramic balls when exposed to Dulbecco's Phosphate Buffered Saline (DPBS). The mechanical interaction of the plurality of ceramic balls can be understood as grounding of the biomaterial. It is further critical to step 604 that sufficient cooling is provided to avoid any deleterious effects on the protein structure of the pericardial material, which may be caused by frictional heat caused by the mechanical interaction of the ceramic balls caused by friction.

[0150] In step 605, the homogenized pericardial material obtained in step 604 may be vortexed for 10 s and may then be centrifuged at 100-500 rpm, preferably 200 rpm, for 1-5 minutes, preferably 1 minute, at 15-30°C, preferably 20°C.

[0151] The homogenized pericardial material can be filled into a syringe in step 606 and can be filled into the prepared glutaraldehyde template / matrix (described above) and can then be frozen at -15-30° C., preferably -20° C., for at least 10-15 hours, preferably at least 12 hours. Due to the formation of ice crystals, the pericardial material can acquire sponge-like properties.

[0152] In step 607, the template / matrix is ​​thawed at room temperature, preferably in a fume hood, for at least 5-10 hours, preferably 6 hours. Thawing is accompanied by cross-linking of the pericardial material.

[0153] The pre-crosslinked pericardial material may be filled into a tube with glutaraldehyde solution in step 608. The pericardial material may then be further crosslinked at 50-70° C., preferably 60° C., for 15-25 hours, preferably 18 hours. For example, a pulse compression step as described herein may be applied to improve / accelerate crosslinking.

[0154] In step 609, the spongy pericardial material can be rinsed in a NaCl solution for 30-90 seconds, preferably at least twice per minute. During the rinsing, a pulse compression step as described herein can be applied to improve / accelerate the rinsing. For example, during the rinsing process, the pericardial material can be compressed with a compression mold every 1-20 seconds, preferably every 5-10 seconds. The rinsing process can be repeated a third time using ultrapure water in addition.

[0155] In step 610, the irrigated pericardial material may be cut into the final desired shape, such as by using a CO2 laser.

[0156] It is important to emphasize that repeated compression of the pericardial material during flushing is beneficial, otherwise it may not be possible to ensure complete removal of the glutaraldehyde solution from the biomaterial. In this regard, the applicant has studied the amount of residual glutaraldehyde solution in the biomaterial after a conventional flushing procedure compared to applying a pulsed compression of the biomaterial as suggested in step 609. The residual amount of glutaraldehyde for two different initial thicknesses of the pericardial material is shown in the table below.

[0157]

[0158] Table 2: Comparison of the remaining glutaraldehyde in the biomaterial sample pieces according to the applied rinsing procedure and the thickness of the biomaterial.

[0159] With respect to Table 2, "conventional irrigation" involved rinsing the pericardial material three times for 60 s in an isotonic NaCl solution while gently moving the pericardial material.

[0160] As shown in Table 2, "pulse compression" involves flushing the pericardial material in an isotonic NaCl solution three times for 60 seconds while gently moving the pericardial material. In addition, the pericardial material is fully compressed with a compression die for a short period of time (eg, 1 second) every five seconds.

[0161] As shown in Table 2, pulse compression of the biomaterial significantly resulted in a reduction in residual glutaraldehyde in the pericardial material. This may help to avoid irreversible damage to the pericardial material during subsequent processing steps.

[0162] In step 611, as a stabilization step, the spongy pericardial material may be rinsed in glycerol (having a concentration of 20-40%, preferably 30%) and ultrapure water for 10-20 minutes, preferably 15 minutes. During the rinsing step, the pericardial material may be repeatedly compressed with a compression time of 1-5 seconds (preferably 2 seconds) and a decompression (relaxation time) of 1-10 seconds (preferably 5 seconds).

[0163] In step 612, the spongy pericardial material can be rinsed in PEG-200 (having a concentration of 20-40%, preferably 40%) and ultrapure water for 10-20 minutes, preferably 15 minutes as a stabilization step. During the rinsing step, the pericardial material can be repeatedly compressed with a compression time of 1-5 seconds (preferably 2 seconds) and a decompression time (relaxation time) of 1-10 seconds (preferably 5 seconds).

[0164] In step 613, the spongy pericardial material can be rinsed in PEG-400 (having a concentration of 20-40%, preferably 40%) and ultrapure water for 10-20 minutes, preferably 15 minutes as a stabilization step. During the rinsing step, the pericardial material can be repeatedly compressed with a compression time of 1-5 s (preferably 2 s) and a decompression time (relaxation time) of 1-10 s (preferably 5 s).

[0165] The stabilized sponge-like material may be further dried in a climate cabinet in step 614. The biomaterial may be preferably placed on an impregnated material impregnated with PEG-400 (at a concentration of 20-40%, preferably 40%) in an environment where the relative humidity may be reduced from 90-99%, preferably 95%, to 5-15%, preferably to 10% within 10-15 hours, preferably within 12 hours.

[0166] In step 615, the dried spongy pericardial material can be placed between two sheets of filter paper and can be compressed with a force of 74 kPa for 1-5 minutes, preferably 1 minute, at room temperature. This final compression can displace excess stabilizing solution from the pores of the spongy material, which can result in a further reduction in the thickness of the biomaterial. In some instances, for this final drying step (as outlined above), it may be preferred to place the pericardial material on an impregnated material, wherein the impregnated material may preferably be impregnated with PEG-400 to avoid unsatisfactory stabilization of the pericardial material due to extraction of the stabilizing solution from the pericardial material (which may otherwise adversely enhance stabilization if the pericardial material is wiped prior to the drying step).

[0167] The pericardial material obtained from the above process can be stored in a reduced thickness (and dry) state until the pericardial material is used in a medical application.

[0168] It is further emphasized that the concentration of the stabilizing solution, the compression force and the choice of filter paper can be considered as the most critical process parameters for the success of the manufacturing method of biomaterials for medical applications. Through the above process, a flexible biomaterial can be obtained, which can be deformable in the dry state (e.g., for attachment to an implant) without rupture.

[0169] As a general illustration, the flexibility of the biomaterial obtained may also depend on the initial thickness of the biomaterial. As an example, a dry sponge-like material having an initial thickness of about 2 mm may achieve a thickness of about 0.8 mm in a dry and compressed state. Although such a material is still flexible and deformable, it may be less flexible than a biomaterial having a thickness of 0.1 mm. Such a material of lesser thickness may also be provided.

[0170] Furthermore, it is emphasized that any of the above compression steps can also be replaced by a corresponding hot pressing step. Hot pressing generally allows stabilizing viscosity changes of the solution.

Claims

1. A method (600) for preparing a porous biomaterial for medical applications, comprising: exposing (611) the biological material to a first liquid; applying (611) a first compression step to the biomaterial, wherein the first compression step comprises repeatedly applying a compressive force at a plurality of compression intervals; and The biological material is dried (615).

2. The method according to claim 1, wherein: Repeatedly applying the compressive force includes alternating compression intervals and at least one relaxation interval of the biomaterial.

3. The method according to claim 2, wherein: The at least one relaxation interval comprises 0.2 s to 30 s, preferably 0.5 s to 15 s.

4. The method according to any one of claims 1 to 3, wherein: The compression interval is comprised between 0.1s and 10s, preferably between 0.2s and 5s.

5. The method according to any one of claims 1 to 4, wherein: The first compressing step comprises applying a compressive force in the range of 25 kPa to 500 kPa, preferably 50 kPa to 450 kPa.

6. The method according to any one of claims 1 to 5, further comprising: After the first compression step, exposing (612) the biomaterial to a second liquid comprising at least 10% of a component other than water; And applying (612) a second compression step to the biomaterial.

7. The method according to claim 6, further comprising: After the second compression step, exposing (613) the biomaterial to a third liquid, the third liquid comprising at least 10% of a component other than water; And applying (613) a third compression step to the biomaterial.

8. The method according to any one of claims 1 to 7, wherein: The drying includes drying the biological material on a material impregnated with the first liquid, the second liquid, and / or the third liquid.

9. The method according to any one of claims 1 to 8, wherein: The method reduces the thickness of the biomaterial by 40% to 80%, preferably 50% to 70%, compared to the initial thickness of the biomaterial.

10. The method according to any one of claims 1 to 9, wherein: The first liquid comprises glycerol and / or polyethylene glycol, preferably at least 10 wt%.

11. The method according to any one of claims 1 to 10, wherein: The biological material is a porous tissue sponge or a pericardial tissue sponge.

12. A biomaterial prepared by the method according to any one of claims 1 to 11.

13. The biomaterial according to claim 12, wherein The biomaterial is swellable upon rehydration to at least 70%, preferably at least 80% of its original thickness; and / or the biomaterial is swellable upon rehydration to at least 70%, preferably at least 80% of its original surface area.

14. An implant comprising the biomaterial according to claim 12 or 13.

15. A biomaterial prepared according to the method of any one of claims 1 to 11 for use as a sealing element of an implant.